Qiagen (QGEN) Stock Looks Reasonable After The Takeover Offer

Qiagen shares have climbed over the past three years while a go private offer now anchors expectations, which puts fresh focus on whether the current price lines up with the cash the business can generate over time.

• The stock has returned 29.6% over 3 years, so a lot of the long term thesis is already reflected in the market value and raises the question of what the underlying cash flows need to support.
• The agreed all cash takeover at €46.50 per share and the plan to delist Qiagen frame a specific payout for existing shareholders. This ties the valuation debate closely to the company’s ability to sustain and grow the cash flows a private owner is paying for.
• If you'd rather focus on earnings, this one's for you. See why Qiagen's 25.4x P/E tells a different valuation story.

The issue now is whether the price implied by the takeover and recent trading is adequately supported by Qiagen’s current and expected cash flows.

If you want to stress test this same cash flow question beyond Qiagen, you can apply the same analysis to a wider set of solid balance sheet and fundamentals stocks screener (25 results).

Does Qiagen Look Fairly Valued on Cash Flow?

The Discounted Cash Flow (DCF) model here focuses on the cash Qiagen can return to shareholders over time rather than near term earnings headlines. Latest twelve month free cash flow sits at about $459.8 million, and analyst projections point to it rising toward the low $600 million range by 2030, then growing only gradually after that, which is closer to a mature profile than a high risk early stage story.

What really matters is how that stream of cash compares with the current share price of $50.22 and the all cash offer at €46.50 that would eventually take Qiagen private. The agreed takeover by EQT Private Equity helps explain why the DCF outcome lines up broadly with where the stock trades today, because the offer effectively places a ceiling on how much of that future cash flow public investors can capture. Find out what Qiagen could be worth using our Discounted Cash Flow (DCF) estimate.

The Qiagen Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the DCF discussion leaves off for Qiagen and explain which combinations of growth, margins and earnings would need to hold for the equity to trade materially above or below today’s level on the Community page. Rather than relying on a single model output, each narrative lays out the assumptions behind its view of fair value so you can track those against future results as they are reported.

Qiagen community views are split into one group that sees extra upside and another that thinks expectations now mostly match the agreed offer.

Bull case: 9% undervalued

"QIAcuity in digital PCR and QIAstat-Dx panel expansion into areas such as bloodstream infection testing, together with companion diagnostics work with pharma partners, broaden the menu in clinically important applications and can support medium term revenue growth and operating leverage..."

Discover why this Narrative puts Qiagen at 9% undervalued.

Bear case: roughly fairly valued

"Qiagen is fairly valued, and the bullish narrative implies that the current share price already reflects disciplined capital returns, progress toward higher EBIT margins and the possibility that any change of control would likely occur at only a moderate premium to today’s valuation..."

Explore why this Narrative puts Qiagen at roughly fairly valued.

One more piece of the Qiagen puzzle to check before you move on

Valuation only tells part of Qiagen's story, since Simply Wall St's broader checks have also flagged specific risk indicators that deserve a look before drawing your own conclusion. Take a closer look at 1 warning sign before settling on a valuation.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com